Clinical use of CAR T-cells in treating acute lymphoblastic leukemia. (April 2023)

• Record Type: Journal Article
• Authors: Korkmaz, Serdal
• Is Part Of: Transfusion and apheresis science. Volume 62:Number 2(2023)
• Publication Date: 2023-04
• Subjects: CAR T-cell -- Clinical use -- Relapse -- Refractory -- Acute lymphoblastic leukemia; Blood -- Transfusion -- Periodicals; Hemapheresis -- Periodicals; 615.39
• DOI: 10.1016/j.transci.2023.103666
• Languages: English
• ISSNs: 1473-0502

Abstract

Abstract: Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment landscape for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). However CAR T-cell therapy of R/R T-ALL has unique challenges, such as the lack of specific tumor antigens, cell fratricide and T cell aplasia, in comparison with that of R/R B-ALL. Despite promising therapeutic outcomes in R/R B-ALL, application of this therapy is limited by high relapse rates and immunological toxicities. Recent studies suggest patients who underwent allogeneic hematopoietic stem cell transplantation post-CAR T-cell therapy would achieve durable remission and better survival, but this remains controversial. Herein, I briefly review published data on the clinical use of CAR T-cells in treating ALL.